How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

6,752 results for

Renin-Angiotensin System

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Comparative effectiveness of renin-angiotensin system inhibitors on renal and cardiovascular outcomes in patients with diabetes and kidney disease: a network meta-analysis

Comparative effectiveness of renin-angiotensin system inhibitors on renal and cardiovascular outcomes in patients with diabetes and kidney disease: a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2020 PROSPERO

122. Association between early worsening renal function and following Outcomes in patients with renin angiotensin system inhibitors treatment: A Meta-Analysis

Association between early worsening renal function and following Outcomes in patients with renin angiotensin system inhibitors treatment: A Meta-Analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2020 PROSPERO

123. The efficacy and safety of renin-angiotensin-aldosterone system inhibitors for the prevention or slowing of diabetic nephropathy in patients with diabetes: A meta-analysis study

The efficacy and safety of renin-angiotensin-aldosterone system inhibitors for the prevention or slowing of diabetic nephropathy in patients with diabetes: A meta-analysis study Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2020 PROSPERO

124. Combination use of medicines from different classes of renin-angiotensin system blocking agents: risk of hyperkalaemia, hypotension, and impaired renal function?new warnings

Combination use of medicines from different classes of renin-angiotensin system blocking agents: risk of hyperkalaemia, hypotension, and impaired renal function?new warnings Combination use of medicines from different classes of renin-angiotensin system blocking agents: risk of hyperkalaemia, hypotension, and impaired renal function—new warnings - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Combination use of medicines from different classes of renin-angiotensin system (...) blocking agents: risk of hyperkalaemia, hypotension, and impaired renal function—new warnings New warnings due to risk of hyperkalaemia, hypotension, and impaired renal function have been agreed following an EU-wide review. Published 11 December 2014 From: Therapeutic area: , , Contents Article date: June 2014 The renin-angiotensin hormone system (RAS) controls blood pressure and the volume of fluids in the body. Medicines that have an inhibitory action on the RAS (RAS blocking agents) are used

2014 MHRA Drug Safety Update

125. Effects of renal denervation on cardiac oxidative stress and local activity of the sympathetic nervous system and renin-angiotensin system in acute myocardial infracted dogs. Full Text available with Trip Pro

Effects of renal denervation on cardiac oxidative stress and local activity of the sympathetic nervous system and renin-angiotensin system in acute myocardial infracted dogs. This study sought to evaluate the therapeutic effects of renal denervation (RDN) on acute myocardial infarction (MI) in canines and explore its possible mechanisms of action.Eighteen healthy mongrel dogs were randomly assigned to either the control group, the MI group or the MI + RDN group. To assess cardiac function, left (...) ) and activity of superoxide dismutase (SOD). To measure the local activity of the sympathetic nervous system (SNS) and renin-angiotensin system (RAS), the levels of tyrosine hydroxylase (TH), angiotensin II (AngII), angiotensin-converting enzyme 2 (ACE2), angiotensin (1-7) [Ang(1-7)] and Mas receptor (MasR) in myocardial tissues were recorded. The expression of TH in renal tissue and serum creatinine were used to assess the effectiveness of the RDN procedure and renal function, respectively.We found that MI

2017 BMC Cardiovascular Disorders

126. Cohort study: Renin-angiotensin system blockers increase risk of angio-oedema

Cohort study: Renin-angiotensin system blockers increase risk of angio-oedema Renin-angiotensin system blockers increase risk of angio-oedema | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Renin-angiotensin system blockers increase risk of angio-oedema Article Text Aetiology Cohort study Renin-angiotensin system blockers increase risk of angio-oedema Massimo Volpe , Giuliano Tocci Statistics from Altmetric.com Commentary on: Toh S

2013 Evidence-Based Medicine

127. Cohort study: Lack of definitive evidence for the use of renin-angiotensin system antagonists for heart failure with preserved ejection fraction

Cohort study: Lack of definitive evidence for the use of renin-angiotensin system antagonists for heart failure with preserved ejection fraction Lack of definitive evidence for the use of renin-angiotensin system antagonists for heart failure with preserved ejection fraction | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies (...) , please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Lack of definitive evidence for the use of renin-angiotensin system antagonists for heart failure with preserved

2013 Evidence-Based Medicine

128. Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement. Full Text available with Trip Pro

Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement. Data are lacking on the effect of a renin-angiotensin system (RAS) inhibitor prescribed after transcatheter aortic valve replacement (TAVR). Treatment with a RAS inhibitor may reverse left ventricular remodeling and improve function.To investigate the association of prescription of a RAS inhibitor and outcomes after TAVR.Retrospective cohort

2018 JAMA

129. Association of renin-angiotensin system genetic polymorphisms and aneurysmal subarachnoid hemorrhage. (Abstract)

Association of renin-angiotensin system genetic polymorphisms and aneurysmal subarachnoid hemorrhage. OBJECTIVE Renin-angiotensin system (RAS) genetic polymorphisms are thought to play a role in cerebral aneurysm formation and rupture. The Cerebral Aneurysm Renin-Angiotensin System (CARAS) study prospectively evaluated common RAS polymorphisms and their relation to aneurysmal subarachnoid hemorrhage (aSAH). METHODS The CARAS study prospectively enrolled aSAH patients and controls at 2 academic

2017 Journal of Neurosurgery

130. Relationship between drugs affecting the renin-angiotensin system and colorectal cancer: The MCC-Spain study. Full Text available with Trip Pro

Relationship between drugs affecting the renin-angiotensin system and colorectal cancer: The MCC-Spain study. The potential protective effect of renin-angiotensin system (RAS) inhibitors is a subject of increasing interest due to their possible role as chemopreventive agents against colorectal cancer (CRC). To evaluate this association, we conducted a case-control study with 2165 cases of colorectal cancer, diagnosed between 2007 and 2012, and 3912 population controls frequency matched (by age

2017 Preventive Medicine

131. Skeletal muscle wasting: new role of nonclassical renin-angiotensin system. (Abstract)

Skeletal muscle wasting: new role of nonclassical renin-angiotensin system. Skeletal muscle can be affected by many physiological and pathological conditions that contribute to the development of muscle weakness, including skeletal muscle loss, inflammatory processes, or fibrosis. Therefore, research into therapeutic treatment alternatives or alleviation of these effects on skeletal muscle is of great importance.Recent studies have shown that angiotensin (1-7) [Ang-(1-7)] - a vasoactive peptide (...) of the nonclassical axis in the renin-angiotensin system (RAS) - and its Mas receptor are expressed in skeletal muscle. Ang-(1-7), through its Mas receptor, prevents or diminishes deleterious effects induced by skeletal muscle disease or injury. Specifically, the Ang-(1-7)-Mas receptor axis modulates molecular mechanisms involved in muscle mass regulation, such as the ubiquitin proteasome pathway, the insulin-like growth factor type 1/Akt (protein kinase B) pathway, or myonuclear apoptosis, and also inflammation

2017 Current opinion in clinical nutrition and metabolic care

132. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Full Text available with Trip Pro

Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Elevated serum aldosterone can be vasculotoxic and facilitate cardiorenal damage. Renin-angiotensin system inhibitors reduce serum aldosterone levels and/or block its effects but can cause hyperkalemia. Patiromer, a nonabsorbed potassium binder, decreases serum potassium in patients with chronic kidney disease on renin-angiotensin system inhibitors (...) . Here we examined the effect of patiromer treatment on serum aldosterone, blood pressure, and albuminuria in patients with chronic kidney disease on renin-angiotensin system inhibitors with hyperkalemia (serum potassium 5.1-6.5 mEq/l). We analyzed data from the phase 3 OPAL-HK study (4-week initial treatment phase of 243 patients; 8-week randomized withdrawal phase of 107 patients). In the treatment phase, the (mean ± standard error) serum potassium was decreased concordantly with the serum

2017 Kidney International Controlled trial quality: uncertain

133. Pediatric Primary Hypertension and the Renin-Angiotensin System (PHRAS)

Pediatric Primary Hypertension and the Renin-Angiotensin System (PHRAS) Pediatric Primary Hypertension and the Renin-Angiotensin System (PHRAS) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Pediatric (...) Primary Hypertension and the Renin-Angiotensin System (PHRAS) (PHRAS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03310684 Recruitment Status : Enrolling by invitation First Posted : October 16, 2017 Last Update Posted : December 21, 2018 Sponsor: Wake Forest University Health Sciences Information

2017 Clinical Trials

134. Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK)

Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK) Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Renal (...) Transplant Injury and the Renin-Angiotensin System in Kids (RETASK) (RETASK) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03317925 Recruitment Status : Completed First Posted : October 23, 2017 Last Update Posted : November 8, 2017 Sponsor: Wake Forest University Health Sciences Collaborator: Stanford

2017 Clinical Trials

135. Cardiovascular effects of small peptides of the renin angiotensin system Full Text available with Trip Pro

Cardiovascular effects of small peptides of the renin angiotensin system The renin-angiotensin system (RAS) is a unique hormonal cascade which is composed by multiple enzymes and effector peptides. Recently, new peptides presenting biological activity have been discovered, increasing the complexity of the RAS Here, we evaluated the effects of small peptides of the RAS in coronary bed of rats. Firstly, we examined the direct effect of small angiotensinergic peptides [Angiotensin (Ang) -(1-5

2017 Physiological reports

136. Progression of Renal Insufficiency in Patients with Essential Hypertension Treated with Renin Angiotensin Aldosterone System Blockers: An Electrocardiographic Correlation Full Text available with Trip Pro

Progression of Renal Insufficiency in Patients with Essential Hypertension Treated with Renin Angiotensin Aldosterone System Blockers: An Electrocardiographic Correlation There is a frequent association between renal insufficiency and cardiovascular disease in patients with essential hypertension (HTN). The aim of this study was to analyze the relationship between ECG parameters and the progress of renal damage in patients with treated HTN.109 patients with HTN had their microalbuminuria

2017 Diseases

137. Renin-angiotensin system inhibitors in patients with or without ischaemic mitral regurgitation after acute myocardial infarction Full Text available with Trip Pro

Renin-angiotensin system inhibitors in patients with or without ischaemic mitral regurgitation after acute myocardial infarction Little is known about the long-term effects of renin-angiotensin system inhibitors (RASI) on cardiovascular events in patients after acute myocardial infarction (AMI) with ischaemic mitral regurgitation (IMR). The purpose of this study was to investigate the association of RASI with the incidence of adverse cardiac events in patients with or without IMR after AMI.We

2017 Open heart

138. Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients on Renin-Angiotensin-Aldosterone-System Inhibitors. Full Text available with Trip Pro

Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients on Renin-Angiotensin-Aldosterone-System Inhibitors. Older people are predisposed to hyperkalemia because of impaired renal function, comorbid conditions, and polypharmacy. Renin-angiotensin-aldosterone system inhibitors (RAASi), which are recommended to treat chronic kidney disease and heart failure augment the risk. Patiromer, a nonabsorbed potassium binder, was shown in the phase 3 OPAL-HK study

2017 American Journal of Medicine Controlled trial quality: uncertain

139. Treatment effects of renin-angiotensin aldosterone system blockade on kidney failure and mortality in chronic kidney disease patients. Full Text available with Trip Pro

Treatment effects of renin-angiotensin aldosterone system blockade on kidney failure and mortality in chronic kidney disease patients. Chronic kidney disease (CKD) is a leading cause of death before and after onset of end-stage renal disease (ESRD). Knowing treatments that can delay disease progression will lead to reduced mortality. We therefore aimed to estimate the effectiveness of renin angiotensin aldosterone system (RAAS) blockade on CKD progression.We conducted a retrospective CKD cohort

2017 BMC Nephrology

140. The renin-angiotensin system: a possible new target for depression. Full Text available with Trip Pro

The renin-angiotensin system: a possible new target for depression. Depression remains a debilitating condition with an uncertain aetiology. Recently, attention has been given to the renin-angiotensin system. In the central nervous system, angiotensin II may be important in multiple pathways related to neurodevelopment and regulation of the stress response. Studies of drugs targeting the renin-angiotensin system have yielded promising results. Here, we review the potential beneficial effects (...) of angiotensin blockers in depression and their mechanisms of action. Drugs blocking the angiotensin system have efficacy in several animal models of depression. While no randomised clinical trials were found, case reports and observational studies showed that angiotensin-converting enzyme inhibitors or angiotensin receptor blockers had positive effects on depression, whereas other antihypertensive agents did not. Drugs targeting the renin-angiotensin system act on inflammatory pathways implicated

2017 BMC Medicine

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>